Syngene International Ltd

Syngene International Ltd

₹ 691 -7.92%
24 Apr 9:09 a.m.
About

Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]

Key Points

Business Footprint:[1]
The company caters to diverse end-user industries like Pharmaceuticals, Animal Health, Agrochemicals, Consumer Packaged Goods, Chemicals/Polymers.
It has 400+ active customers with engagements with 13 out of the top 15 global pharma companies. The company holds 400+ patents jointly with clients and has a base of 6000+ scientists.

  • Market Cap 27,801 Cr.
  • Current Price 691
  • High / Low 961 / 608
  • Stock P/E 62.6
  • Book Value 115
  • Dividend Yield 0.18 %
  • ROCE 13.1 %
  • ROE 10.0 %
  • Face Value 10.0

Pros

  • Company is almost debt free.

Cons

  • Stock is trading at 6.50 times its book value
  • The company has delivered a poor sales growth of 10.9% over past five years.
  • Company has a low return on equity of 11.7% over last 3 years.
  • Dividend payout has been low at 10.7% of profits over last 3 years
  • Promoter holding has decreased over last 3 years: -17.7%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
759 644 768 787 994 716 831 792 865 726 821 877 948
509 473 552 556 678 552 614 592 565 578 613 626 638
Operating Profit 249 172 216 230 316 163 217 200 299 148 209 251 310
OPM % 33% 27% 28% 29% 32% 23% 26% 25% 35% 20% 25% 29% 33%
15 16 15 17 23 23 14 25 15 50 16 18 18
Interest 6 9 12 14 10 6 9 6 8 7 7 7 10
Depreciation 80 86 90 95 88 89 91 94 96 92 94 92 90
Profit before tax 178 92 129 139 241 92 131 125 210 99 124 170 229
Tax % 17% 20% 21% 21% 21% 18% 22% 20% 10% 25% 22% 28% 24%
147 73 102 110 189 75 102 100 190 74 97 123 174
EPS in Rs 3.67 1.82 2.53 2.73 4.71 1.87 2.53 2.48 4.72 1.84 2.40 3.06 4.33
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
700 860 1,107 1,201 1,423 1,826 2,012 2,179 2,601 3,194 3,203 3,373
485 579 727 816 950 1,290 1,395 1,504 1,861 2,252 2,322 2,456
Operating Profit 214 281 380 385 473 536 617 676 741 942 881 918
OPM % 31% 33% 34% 32% 33% 29% 31% 31% 28% 29% 28% 27%
8 12 6 94 53 75 153 94 75 63 74 102
Interest 0 8 8 18 23 32 35 28 24 45 30 31
Depreciation 66 81 97 114 131 164 219 274 310 359 369 367
Profit before tax 157 204 281 346 372 414 516 467 482 601 557 622
Tax % 14% 14% 14% 17% 18% 20% 20% 14% 18% 21% 16% 25%
135 175 241 287 305 331 412 404 394 473 466 468
EPS in Rs 12.45 4.38 6.02 7.18 7.63 8.27 10.29 10.09 9.83 11.78 11.60 11.63
Dividend Payout % 0% 239% 8% 7% 7% 3% 0% 0% 10% 11% 11% 11%
Compounded Sales Growth
10 Years: 15%
5 Years: 11%
3 Years: 9%
TTM: 5%
Compounded Profit Growth
10 Years: 10%
5 Years: 4%
3 Years: 2%
TTM: -5%
Stock Price CAGR
10 Years: %
5 Years: 20%
3 Years: 6%
1 Year: 8%
Return on Equity
10 Years: 15%
5 Years: 13%
3 Years: 12%
Last Year: 10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 26 199 200 200 200 200 400 400 401 401 402 402
Reserves 633 646 825 1,213 1,520 1,767 1,774 2,418 2,891 3,218 3,790 4,236
155 155 891 806 787 813 773 893 1,022 639 332 306
377 422 440 555 681 922 1,215 1,166 1,247 1,590 1,310 1,462
Total Liabilities 1,191 1,422 2,356 2,775 3,188 3,702 4,162 4,878 5,561 5,848 5,834 6,407
394 503 580 810 1,030 1,377 2,020 2,201 2,393 2,260 2,318 2,246
CWIP 45 105 237 175 155 274 234 237 346 126 760 875
Investments 352 146 277 540 158 716 777 702 1,034 941 928 1,468
399 667 1,262 1,249 1,845 1,336 1,132 1,737 1,787 2,521 1,829 1,818
Total Assets 1,191 1,422 2,356 2,775 3,188 3,702 4,162 4,878 5,561 5,848 5,834 6,407

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
300 18 308 398 446 630 677 698 582 838 913
-375 16 -753 -470 -350 -646 -424 -629 -611 -685 -383
155 -10 716 -81 -79 -72 -226 58 -31 -340 -536
Net Cash Flow 80 24 272 -153 17 -88 28 127 -60 -187 -6

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 49 76 61 60 68 68 72 79 71 55 49 51
Inventory Days 28 59 44 37 82 30 18 41 87 141 95 62
Days Payable 146 106 87 116 194 154 157 166 115 110 104 143
Cash Conversion Cycle -68 29 18 -19 -44 -56 -67 -45 44 86 41 -30
Working Capital Days -61 -6 -10 -14 -28 -65 -115 -19 -4 32 -22 20
ROCE % 23% 23% 20% 18% 16% 17% 17% 14% 13% 15% 13% 13%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
70.29% 64.86% 64.86% 54.88% 54.80% 54.79% 54.79% 54.79% 54.72% 54.72% 52.74% 52.74%
14.15% 16.79% 16.87% 23.31% 23.19% 23.55% 21.20% 20.92% 20.64% 20.72% 20.65% 19.47%
4.18% 6.75% 7.03% 10.71% 11.20% 11.70% 14.63% 15.80% 16.78% 17.49% 19.52% 21.50%
10.56% 11.11% 10.77% 10.65% 10.23% 9.47% 9.07% 8.18% 7.44% 6.74% 6.79% 5.99%
0.83% 0.49% 0.47% 0.46% 0.60% 0.48% 0.32% 0.31% 0.43% 0.34% 0.29% 0.29%
No. of Shareholders 1,28,2781,34,3341,27,9641,24,0141,25,4551,25,9921,21,8801,15,8501,20,0181,07,3381,28,8061,25,090

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls